Search Results - Lee, Alexandria T.M.

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive

    LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive by Ou, Sai-Hong Ignatius, Lee, Alexandria T.M

    Published in Lung cancer (Auckland)
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Overcoming Central [beta]-Sheet #6

    Overcoming Central [beta]-Sheet #6 by Ou, Sai-Hong Ignatius, Lee, Alexandria T.M

    Published in Lung cancer (Auckland)
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Overcoming Central [beta]-Sheet #6 ALK TKI Must Deliver

    Overcoming Central [beta]-Sheet #6 ALK TKI Must Deliver by Lee, Alexandria T.M, Ou, Sai-Hong Ignatius

    Published in Lung cancer (Auckland)
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC by Ou, Sai-Hong Ignatius, Lee, Alexandria T.M., Nagasaka, Misako

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Letter to Editor. Re “de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer,” Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?

    Letter to Editor. Re “de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer,” Semaglutide a Potential Treatment for Serious W... by Lee, Alexandria T.M., Ou, Sai-Hong Ignatius, Lisberg, Aaron

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC

    CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC by Lee, Alexandria T M, Nagasaka, Misako

    Published in Lung cancer (Auckland)
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver

    Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Gener... by Lee, Alexandria T M, Ou, Sai-Hong Ignatius

    Published in Lung cancer (Auckland)
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  8. 8
    LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

    LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, A... by Lee, Alexandria T M, Ou, Sai-Hong Ignatius

    Published in Lung cancer (Auckland)
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  9. 9
    From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

    From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting by Lee, Alexandria T M, Ou, Saihong Ignatius

    Published in Lung cancer (Auckland)
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  10. 10
    ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

    ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia by Lee, Alexandria T M, Ou, Saihong Ignatius

    Published in Lung cancer (Auckland)
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: